DATA GRAPHICS | Deals
MiNA leads in RNA therapeutics deals : Data Byte
May 12, 2021 12:48 AM UTC
A small activating RNA partnership with Lilly gives MiNA the largest deal count and total disclosed deal value for RNA therapeutics, defined as therapies that deliver or stimulate production of RNA, since January 2020.
Tuesday’s deal with Eli Lilly and Co. (NYSE:LLY) is the latest sign of momentum for MiNA Therapeutics Ltd., which raised £23 million ($29.4 million) in a September series A round led by aMoon. Having financed itself for 12 years via high-net-worth individuals and Sosei, the company sought its first institutional round after reporting early clinical data from lead program MTL-CEBPA at the 2020 American Society of Clinical Oncology (ASCO) meeting...